Overview
Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2022-09-01
2022-09-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
Our study aims at assessment of response, survival and toxicity of frontline treatment with chemotherapy and Bevacizumab in patients having advanced epithelial ovarian cancer.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Nada Hassan SalahCollaborator:
Assiut UniversityTreatments:
Bevacizumab
Criteria
Inclusion Criteria:- Female patients diagnosed with advanced ovarian cancer by biopsy
- Age more than 18 years old
- Routine labs are within normal values ( CBC, renal function tests , liver function
tests )
- Performance score 0-2
- FIGO stage II-IV
- Not having any contraindication to bevacizumab as : uncontrolled hypertension ,
bleeding tendency , ischaemic events
- Chemotherapy naïve.
- Informed consent
Exclusion Criteria:
- patients previously received chemotherapy or radiotherapy to any part of the abdomen
or pelvis
- patients with uncontrolled infection
- patients with clinically significant cardiovascular disease
- patients with active bleeding or conditions associated with high risk of bleeding
- patients with history of CNS disease